abstract |
The invention is based on the identification of a novel splice variant of human cannabinoid 1 (CB1) receptor, termed CB1b, and its use in the identification of therapeutic agents and in the diagnosis, prevention and treatment of CB associated disorders such as obesity, psychiatric, pain and neurological disorders. |